

## CANADIAN CANCER TRIALS GROUP

## LUNG

DISEASE SITE COMMITTEE MEETING AGENDA

Saturday 29 April 2017, 1:30-4:15 PM

Chelsea Hotel, Toronto

Room: Churchill A

Chairs: G. Goss / Y. Ung

Objectives:

To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to the management of lung cancer

To cite and analyze recent results of lung cancer clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group

---

1:30 – 1:35 pm	<b>Welcome and Introduction</b>	<b>G. Goss/Y. Ung</b>
1:35 – 2:15 pm	<b><u>Report from Trial Study Chairs: Update on Current Trials:</u></b>	
1:35 – 1:45	<b><u>PM.1/CAPTUR</u></b> Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) - A Phase II Basket Trial	<b>F. Vera-Badillo</b>
1:45 – 1:55	<b><u>BR.31:</u></b> A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer	<b>G. Goss</b>
1:55 – 2:05	<b><u>BRC.6 (LungMAP – S1400):</u></b> A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer	<b>N. Leighl</b>
2:05 – 2:15	<b><u>BR.34:</u></b> A Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab +/- Platinum-Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	<b>N. Leighl</b>
2:15 – 2:30 pm	<b><u>Coffee Break</u></b>	

**IND Studies**

2:30 – 2:40	<b><u>IND.214</u></b> A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients with Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours	<b>D. Jonker</b>
2:40 – 2:50	<b><u>IND.219:</u></b> A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-Based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer	<b>B. Melosky</b>
2:50 – 3:00	<b><u>IND.226:</u></b> A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens	<b>R. Juergens/D. Hao</b>
3:00 – 3:10	<b><u>IND.227:</u></b> A Phase II Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma	<b>Q. Chu</b>

**Reports from Committees**

3:10 - 3:15	<b>IND Committee</b>	<b>S. Laurie</b>
3:15 – 3:20	<b>Lung CSTB</b>	<b>M. Tsao</b>
3:20 - 3:25	<b>Small Cell/Radiation Subcommittee</b>	<b>P. Ellis</b>
3:25 – 3:30	<b>Mesothelioma/Thymoma</b>	<b>C. Lee</b>

**New Concepts and Proposals**

3:30 – 4:15	<b>Proposed trials:</b>	<b>G. Goss</b>
	Osimertinib + Cediranib, first line, in EGFRm NSCLC	<b>B. Melosky</b>
	Others	<b>TBD</b>
4.15 pm	<b>Summary and Close</b>	<b>G. Goss/Y. Ung</b>